08-04-2026 | Analyze. Execute. Alpha.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Next earning release is on 2026-05-12 00:00:00, in NA days

Hourly Momentum

Daily Framework

Weekly Strategic
Premium Analysis Locked